High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: Results of a randomized multicenter clinical trial

G. Mustacchi, L. Pavesi, S. Milani, V. Iaffaioli, A. Caraco, G. Comella, A. Contu, A. Farris, G. Artado-Parinello, M. Narcisi, F. Brema, A. Beni, C. Bumma

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The purpose of this study was to ascertain the possible protective effect of thymostimulin (TS) on chemotherapy-induced leukopenia and related febrile episodes, beside the potential of improving therapeutic efficacy and tolerability of high-dose folinic acid (FA) plus fluorouracil (FU) in metastatic colorectal cancer. In 211 evaluable patients the objective responses were 19/105 (18%) in the FA-FU arm versus 32/106 (30%) obtained with the same regimen plus TS. The difference was statistically significant (p = 0.02). No difference was observed in terms of hematological toxicity, while the TS treated patients experienced a significantly lower incidence of mucositits and diarrhoea (p = 0.03). No significant differences were recorded in the incidence of febrile episodes and other treatment-related toxicities. The possibility of improving response to chemotherapy in advanced colorectal cancer without increasing systemic toxicity is particularly interesting and deserves further attention.

Original languageEnglish
Pages (from-to)617-619
Number of pages3
JournalAnticancer Research
Volume14
Issue number2 B
Publication statusPublished - 1994

Fingerprint

Leucovorin
Fluorouracil
Multicenter Studies
Colorectal Neoplasms
Randomized Controlled Trials
Fever
Drug Therapy
Incidence
Leukopenia
Diarrhea
Therapeutics
thymostimulin

Keywords

  • Colorectal cancer
  • Folinic acid
  • Modulation
  • Thymostimulin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer : Results of a randomized multicenter clinical trial. / Mustacchi, G.; Pavesi, L.; Milani, S.; Iaffaioli, V.; Caraco, A.; Comella, G.; Contu, A.; Farris, A.; Artado-Parinello, G.; Narcisi, M.; Brema, F.; Beni, A.; Bumma, C.

In: Anticancer Research, Vol. 14, No. 2 B, 1994, p. 617-619.

Research output: Contribution to journalArticle

Mustacchi, G, Pavesi, L, Milani, S, Iaffaioli, V, Caraco, A, Comella, G, Contu, A, Farris, A, Artado-Parinello, G, Narcisi, M, Brema, F, Beni, A & Bumma, C 1994, 'High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: Results of a randomized multicenter clinical trial', Anticancer Research, vol. 14, no. 2 B, pp. 617-619.
Mustacchi, G. ; Pavesi, L. ; Milani, S. ; Iaffaioli, V. ; Caraco, A. ; Comella, G. ; Contu, A. ; Farris, A. ; Artado-Parinello, G. ; Narcisi, M. ; Brema, F. ; Beni, A. ; Bumma, C. / High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer : Results of a randomized multicenter clinical trial. In: Anticancer Research. 1994 ; Vol. 14, No. 2 B. pp. 617-619.
@article{344190e4e3f649d68b67da42ddb4c4da,
title = "High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: Results of a randomized multicenter clinical trial",
abstract = "The purpose of this study was to ascertain the possible protective effect of thymostimulin (TS) on chemotherapy-induced leukopenia and related febrile episodes, beside the potential of improving therapeutic efficacy and tolerability of high-dose folinic acid (FA) plus fluorouracil (FU) in metastatic colorectal cancer. In 211 evaluable patients the objective responses were 19/105 (18{\%}) in the FA-FU arm versus 32/106 (30{\%}) obtained with the same regimen plus TS. The difference was statistically significant (p = 0.02). No difference was observed in terms of hematological toxicity, while the TS treated patients experienced a significantly lower incidence of mucositits and diarrhoea (p = 0.03). No significant differences were recorded in the incidence of febrile episodes and other treatment-related toxicities. The possibility of improving response to chemotherapy in advanced colorectal cancer without increasing systemic toxicity is particularly interesting and deserves further attention.",
keywords = "Colorectal cancer, Folinic acid, Modulation, Thymostimulin",
author = "G. Mustacchi and L. Pavesi and S. Milani and V. Iaffaioli and A. Caraco and G. Comella and A. Contu and A. Farris and G. Artado-Parinello and M. Narcisi and F. Brema and A. Beni and C. Bumma",
year = "1994",
language = "English",
volume = "14",
pages = "617--619",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer

T2 - Results of a randomized multicenter clinical trial

AU - Mustacchi, G.

AU - Pavesi, L.

AU - Milani, S.

AU - Iaffaioli, V.

AU - Caraco, A.

AU - Comella, G.

AU - Contu, A.

AU - Farris, A.

AU - Artado-Parinello, G.

AU - Narcisi, M.

AU - Brema, F.

AU - Beni, A.

AU - Bumma, C.

PY - 1994

Y1 - 1994

N2 - The purpose of this study was to ascertain the possible protective effect of thymostimulin (TS) on chemotherapy-induced leukopenia and related febrile episodes, beside the potential of improving therapeutic efficacy and tolerability of high-dose folinic acid (FA) plus fluorouracil (FU) in metastatic colorectal cancer. In 211 evaluable patients the objective responses were 19/105 (18%) in the FA-FU arm versus 32/106 (30%) obtained with the same regimen plus TS. The difference was statistically significant (p = 0.02). No difference was observed in terms of hematological toxicity, while the TS treated patients experienced a significantly lower incidence of mucositits and diarrhoea (p = 0.03). No significant differences were recorded in the incidence of febrile episodes and other treatment-related toxicities. The possibility of improving response to chemotherapy in advanced colorectal cancer without increasing systemic toxicity is particularly interesting and deserves further attention.

AB - The purpose of this study was to ascertain the possible protective effect of thymostimulin (TS) on chemotherapy-induced leukopenia and related febrile episodes, beside the potential of improving therapeutic efficacy and tolerability of high-dose folinic acid (FA) plus fluorouracil (FU) in metastatic colorectal cancer. In 211 evaluable patients the objective responses were 19/105 (18%) in the FA-FU arm versus 32/106 (30%) obtained with the same regimen plus TS. The difference was statistically significant (p = 0.02). No difference was observed in terms of hematological toxicity, while the TS treated patients experienced a significantly lower incidence of mucositits and diarrhoea (p = 0.03). No significant differences were recorded in the incidence of febrile episodes and other treatment-related toxicities. The possibility of improving response to chemotherapy in advanced colorectal cancer without increasing systemic toxicity is particularly interesting and deserves further attention.

KW - Colorectal cancer

KW - Folinic acid

KW - Modulation

KW - Thymostimulin

UR - http://www.scopus.com/inward/record.url?scp=0028103568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028103568&partnerID=8YFLogxK

M3 - Article

C2 - 8010718

AN - SCOPUS:0028103568

VL - 14

SP - 617

EP - 619

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -